Sabra Health Care REIT Sees FY24 Normalized AFFO $1.39-$1.43
Sabra Health Care REIT Sees FY24 Normalized AFFO $1.39-$1.43
2024 GUIDANCE
2024 年指南
Sabra is reiterating 2024 earnings guidance ranges as follows (attributable to common stockholders, per diluted common share):
Sabra重申了2024年的收益指導區間如下（歸屬於普通股股東，攤薄後的每股普通股）：
- Net Income: $0.53 - $0.57
- FFO: $1.33 - $1.37
- Normalized FFO: $1.34 - $1.38
- AFFO: $1.38 - $1.42
- Normalized AFFO: $1.39 - $1.43
- 淨收入：0.53 美元-0.57 美元
- FFO：1.33 美元-1.37 美元
- 標準化 FFO：1.34 美元-1.38 美元
- AFFO：1.38 美元-1.42 美元
- 標準化 AFFO：1.39 美元-1.43 美元
Earnings guidance above assumes no 2024 acquisition or disposition activity.
上述收益指引假設2024年沒有收購或處置活動。
Commenting on the first quarter's results, Rick Matros, CEO and Chair, said, "As has been evident for several quarters, Sabra's portfolio continues to grow stronger, whether looking at coverage, occupancy, or NOI. Trailing-twelve-month SNF coverage saw a healthy 0.06x increase sequentially, to 1.79x, when excluding the impact of Provider Relief Funds. Our SHOP portfolio continues to improve, and this quarter's results - which faced a challenging year-over-year comp - are in line with our expectations embedded in guidance. Our balance sheet remains strong and is poised to support future growth.
首席執行官兼董事長裏克·馬特羅斯在評論第一季度的業績時表示：“正如幾個季度所證明的那樣，無論是從承保範圍、入住率還是NOI來看，Sabra的投資組合都持續增強。如果不包括提供者救濟資金的影響，過去十二個月的SNF覆蓋率連續增長了0.06倍，達到1.79倍。我們的SHOP投資組合持續改善，本季度的業績——同比增長面臨挑戰——符合我們在指導中提出的預期。我們的資產負債表仍然強勁，有望支持未來的增長。
Although we have no new investments to discuss this quarter, the pipeline has improved and with what we are working on, we expect to announce new investments on our second quarter call."
儘管本季度我們沒有新的投資可以討論，但渠道有所改善，根據我們正在進行的工作，我們預計將在第二季度電話會議上宣佈新的投資。”
譯文內容由第三人軟體翻譯。